If PKCe levels allow Alkon to predict if someone will get Alzheimers with a 95%(!) accuracy rate, I'd say that's pretty much proof that he has found one of the earliest causes of the disease, which if normalized leads to a cognitive improvement that is consistent with what the compassionate use patients showed, i.e. reversal of the disease.
Combine that with the fact that phase 2 patients have asked to be included in further trials in order to keep receiving the drug, and suddenly you start to see a pattern.
As for arguments that Bryostatin causes seizures, I suggest you read about the more than a thousand cancer patients that experienced no side effects whatsoever except some muscle pain, which is easily treated with painkillers. Those trials were also performed with a much higher dose than what is used here.
Then there are arguments about the length of the trial, where I assume people have a suspicion that a longer trial would show side effects eventually. These people however seem to have looked over the fact that Alkon specifically mentioned treating one patient for 7 months before they were unable to continue (most likely due to death from age-related disease).
It wouldn't surprise me if the phase 2 trials show some adverse events, as some of the patients are so old that a mental recovery wouldn't stop their other organs from failing due to old age. What I do expect however is a reversal of cognitive decline in the patients that do manage to stay alive for the entire duration of the trials.
Market Data 
Markets 
AI
